Swayampakula Ramakanth, an analyst from H.C. Wainwright, maintained the Buy rating on AbSci (ABSI – Research Report). The associated price ...

Ocugen has dosed the first subject in a multicentre Phase I trial of OCU200 for diabetic macular oedema (DMO) treatment.

X4 Pharmaceuticals (XFOR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Swayampakula ...

The hefty tariffs President-elect Trump has pledged to levy on U.S. imports could impact the price and availability of pharmaceutical drugs. Trump has floated 25 percent tariffs on imports from ...

Shares of Ocugen Inc. OCGN sank 0.45% to $0.81 Tuesday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 5,881.63 and Dow ...

President-elect Trump’s plan to enact heavy tariffs on certain imports could affect the prices and availability of pharmaceutical drugs in the U.S. Trump has floated 25 percent tariffs on ...

Ocugen is a biopharmaceutical company that discovers ... a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your ...

Ocugen is a biopharmaceutical company that discovers ... a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center. Give your ...

A Reuters analysis of prices for new drugs found that pharmaceutical companies launched new U.S. drugs in 2023 at prices 35% higher than in 2022. The over 250 drug hikes represent an increase from ...

This scenario indicates that 2025 will be a promising year for the pharma sector. A report by Axis Securities last month outlined a positive outlook for the pharmaceutical sector over the next three ...

Maxim Group has recently initiated Ocugen Inc (OCGN) stock to Buy rating, as announced on October 15, 2024, according to Finviz. Earlier, on March 1, 2023, Chardan Capital Markets had raised the stock ...